Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants An Open, Randomized Trial


Por: Arribas, JMM, Martinez, AC, Horn, M, Porcuna, XMP, Reigada, MDO, Bermudez, JM, Malfaz, FC, Miranda, M, Mendez, M, Cabezas, MAG, Wittermann, C, Bleckmann, G, Fischbach, T, Kolhe, D, van der Wielen, M and Baine, Y

Publicada: 1 abr 2017
Resumen:
Background: This was the first study evaluating the immunogenicity and safety of the quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) coadministered with routine childhood vaccines in young infants. Methods: In this open, randomized, controlled, phase III study (NCT01144663), 2095 infants (ages 6-12 weeks) were randomized (1: 1: 1: 1) into 4 groups to receive MenACWY-TT at 2, 3, 4 and 12 months of age, or MenACWY-TT, MenC-cross-reactive material (CRM197) or MenC-TT at 2, 4 and 12 months of age. All participants received PHiD-CV and DTPa-HBV-IPV/Hib at 2, 3, 4 and 12 months of age. Immune responses were measured by serum bactericidal activity assays using rabbit (rSBA) and human (hSBA) complement. Solicited and unsolicited symptoms were recorded during 8 and 31 days post-vaccination, respectively, and serious adverse events throughout the study. Results: Noninferiority of immune responses to MenC induced by 2 or 3 doses of MenACWY-TT versus 2 doses of MenC-TT or MenC-CRM197 was demonstrated. Predefined criteria for the immunogenicity of MenACWY-TT to MenA, MenW and MenY were met. One month after 2 or 3 primary MenACWY-TT doses, >= 93.1% and >= 88.5% of infants had rSBA and hSBA titers >= 1: 8 for all serogroups. The robust increases in rSBA and hSBA titers observed for all vaccine serogroups postbooster vaccination suggested that MenACWY-TT induced immune memory. MenACWY-TT coadministered with childhood vaccines had a clinically acceptable safety profile. Conclusions: This study supports the coadministration of MenACWY-TT with routine childhood vaccines as 2 or 3 primary doses during infancy followed by a booster dose in the second year of life.

Filiaciones:
Arribas, JMM:
 Hosp Univ Burgos, Dept Pediat, Ave Islas Baleares, Burgos, Spain

Martinez, AC:
 Inst Hispalense Pediatria, C Jardin Isla 6,Edificio Expolocal, Seville, Spain

Horn, M:
 Pediat Off Dr Horn, Schoenau, Germany

Porcuna, XMP:
 Manlleu Primary Care Ctr, Osona, Spain

Reigada, MDO:
 Hosp La Fe, Dept Pediat, Valencia, Spain

Bermudez, JM:
 Inst Pediat Mares Riera, Pediatria, Blanes, Spain

Malfaz, FC:
 Rio Hortega Univ Hosp, Dept Pediat, Valladolid, Spain

Miranda, M:
 Hosp Antequera, Dept Pediat, Antequera, Spain

:
 Hosp Badalona Germans Trias & Pujol, Badalona, Spain

Cabezas, MAG:
 Hosp Gen Univ Ciudad Real, Ciudad Real, Spain

Wittermann, C:
 Study Ctr Weilheim, Pediat Practice Weilheim, Oberbayern, Germany

Bleckmann, G:
 Private Practice Bleckmann, Baunatal, Germany

Fischbach, T:
 Private Practice Fischbach, Solingen, Germany

Kolhe, D:
 GSK Pharmaceut, Bangalore, Karnataka, India

van der Wielen, M:
 GSK Vaccines, Vaccine Dev & Discovery Dept, Wavre, Belgium

Baine, Y:
 GSK Vaccines, 216 Edgehill Rd, Merion, PA 19066 USA
ISSN: 08913668





Pediatric Infectious Disease Journal
Editorial
Lippincott Williams & Wilkins Ltd., TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 36 Número: 4
Páginas: 98-107
WOS Id: 000396222900004
ID de PubMed: 28002359

MÉTRICAS